AAAAAA
Results:
1-13
|
Results: 13
Authors:
Thompson, IM
Tangen, CM
Tolcher, A
Crawford, ED
Eisenberger, M
Moinpour, CM
Citation: Im. Thompson et al., Association of African-American ethnic background with survival in men with metastatic prostate cancer, J NAT CANC, 93(3), 2001, pp. 219-225
Authors:
Thompson, IM
Tangen, CM
Tolcher, A
Crawford, ED
Eisenberger, M
Moinpour, CM
Citation: Im. Thompson et al., Re: Association of African-American ethnic background with survival in menwith metastatic prostate cancer - Response, J NAT CANC, 93(15), 2001, pp. 1175-1175
Authors:
Hidalgo, M
Siu, LL
Nemunaitis, J
Rizzo, J
Hammond, LA
Takimoto, C
Eckhardt, SG
Tolcher, A
Britten, CD
Denis, L
Ferrante, K
Von Hoff, DD
Silberman, S
Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J CL ONCOL, 19(13), 2001, pp. 3267-3279
Authors:
Leung, S
Miyake, H
Zellweger, T
Tolcher, A
Gleave, ME
Citation: S. Leung et al., Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model, INT J CANC, 91(6), 2001, pp. 846-850
Authors:
Miayake, H
Tolcher, A
Gleave, ME
Citation: H. Miayake et al., Chemosensitization and delayed androgen-independent recurrence of prostatecancer with the use of antisense Bcl-2 oligodeoxynucleotides, J NAT CANC, 92(1), 2000, pp. 34-41
Authors:
Gelmon, KA
Latreille, J
Tolcher, A
Genier, L
Fisher, B
Forand, D
D'Aloisio, S
Vernillet, L
Daigneault, L
Lebecq, A
Besenval, M
Eisenhauer, E
Citation: Ka. Gelmon et al., Phase I dose-finding study of a new taxane, RPR 109881A, administered as aone-hour intravenous infusion days 1 and 8 to patients with advanced solidtumors, J CL ONCOL, 18(24), 2000, pp. 4098-4108
Authors:
Rowinsky, EK
Johnson, TR
Geyer, CE
Hammond, LA
Eckhardt, SG
Drengler, R
Smetzer, L
Coyle, J
Rizzo, J
Schwartz, G
Tolcher, A
Von Hoff, DD
De Jager, RL
Citation: Ek. Rowinsky et al., DX-8951f, a hexacyclic camptothecin analog, on a daily times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies, J CL ONCOL, 18(17), 2000, pp. 3151-3163
Authors:
Gleave, M
Tolcher, A
Miyake, H
Nelson, C
Brown, B
Beraldi, E
Goldie, J
Citation: M. Gleave et al., Progression to androgen independence is delayed by adjuvant treatment withantisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model, CLIN CANC R, 5(10), 1999, pp. 2891-2898
Authors:
Gelmon, KA
Tolcher, A
Diab, AR
Bally, MB
Embree, L
Hudon, N
Dedhar, C
Ayers, D
Eisen, A
Melosky, B
Burge, C
Logan, P
Mayer, LD
Citation: Ka. Gelmon et al., Phase I study of liposomal vincristine, J CL ONCOL, 17(2), 1999, pp. 697-705
Authors:
Gelmon, K
Eisenhauer, E
Bryce, C
Tolcher, A
Mayer, L
Tomlinson, E
Zee, B
Blackstein, M
Tomiak, E
Yau, J
Batist, G
Fisher, B
Iglesias, J
Citation: K. Gelmon et al., Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer, J CL ONCOL, 17(10), 1999, pp. 3038-3047
Authors:
Gleave, ME
Miayake, H
Goldie, J
Nelson, C
Tolcher, A
Citation: Me. Gleave et al., Targeting bcl-2 gene to delay androgen-independent progression and enhancechemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides, UROLOGY, 54(6A), 1999, pp. 36-46
Authors:
Miyake, H
Tolcher, A
Gleave, ME
Citation: H. Miyake et al., Antisense BcI-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model, CANCER RES, 59(16), 1999, pp. 4030-4034
Authors:
Gelmon, KA
Tolcher, A
O'Reilly, S
Campbell, C
Bryce, C
Shenkier, T
Ragaz, J
Ayers, D
Nakashima, L
Rielly, S
Dulude, H
Citation: Ka. Gelmon et al., A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer, ANN ONCOL, 9(11), 1998, pp. 1247-1249
Risultati:
1-13
|